[Treatment strategies for pediatric patients with primary cardiac tumors]

Li-sheng Qiu1, Yan-juan Sun, Wen-xiang Ding

  • 1Department of Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai 200127, China.

Insights

Treatment strategies for pediatric primary cardiac tumors vary. Surgery is recommended for symptomatic cases, while asymptomatic patients require close monitoring. Restoring normal heart function is the primary goal, not just complete tumor removal.

Area of Science:

  • Pediatric Cardiology
  • Cardiac Oncology
  • Pediatric Surgery

Context:

  • Primary cardiac tumors are rare in children, often presenting with significant symptoms.
  • Echocardiography is crucial for diagnosis and monitoring.
  • A majority of diagnosed pediatric cardiac tumors occur in infants under one year old.

Purpose:

  • To analyze treatment strategies for pediatric primary cardiac tumors.
  • To evaluate the outcomes of surgical and non-surgical interventions.
  • To determine the factors influencing morbidity and mortality in this population.

Summary:

  • This retrospective study analyzed 27 pediatric patients with primary cardiac tumors, with 22 undergoing surgery. Histologies included rhabdomyomas, fibromas, hemangiomas, myxomas, and sarcomas.
  • Surgical outcomes varied, with complete resection in 14 patients and partial in 8. Postoperative complications included low cardiac output and arrhythmias, with 4 in-hospital deaths.
  • Follow-up revealed tumor regression in some cases (rhabdomyomas) and stability in others (fibrosarcoma, hemangioma), with no recurrence of myxomas.

Impact:

  • Individualized therapy is essential for pediatric primary cardiac tumors.
  • Surgery is indicated for symptomatic patients, prioritizing hemodynamic restoration over complete resection alone.
  • Close follow-up is crucial for all patients, regardless of initial treatment, to manage potential complications and monitor tumor status.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...